We thus propose that BET inhibition of p60AmotL2-expressing invasive cancer cells leads to a shift towards pro-apoptotic p53-related signaling pathways, ultimately leading to increased cell death relative to iBET151-treated control cells. The gene discussed is TP53; the disease is cancer.